The upper limit of linearity was 5000 [micro]g/L for codeine, 8000 [micro]g/L for morphine, 6000 [micro]g/L for hydrocodone, and 3000 [micro]g/L for hydromorphone
Codeine, morphine, hydrocodone, and hydromorphone
used to prepare calibrators and controls were obtained from Sigma Chemical Co.
Acura Pharmaceuticals said it must complete Phase I development of its hydromorphone
tablet by 28 February 2015, to optimise the formulation in preparation for clinical testing in Phase II.
M2 EQUITYBITES-January 27, 2012-Elite Pharmaceuticals Inc receives FDA approval for supplemental application for manufacturing Hydromorphone
USP 8 mg(C)2012 M2 COMMUNICATIONS http://www.
The extended-release formulation of hydromorphone
is under FDA review for approval as a treatment for moderate to severe pain in opioid-tolerant patients.
is more commonly being used as an alternative analgesic agent for pain control, since it is less lipophilic than morphine and "sticks where you put it.
Of 728 women who had spontaneous labor or spontaneous rupture of membranes, those who received intrathecal fentanyl when cervical dilation was less than 4 cm did not face an increased risk of having a cesarean section and had a shorter duration of labor, compared with those who received systemic hydromorphone
early in labor.
LOUIS -- Covidien (NYSE: COV), a leading global provider of healthcare products, today introduced EXALGO[TM] (hydromorphone
HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone
treatment available in the United States.
Contract award notice: statements not exclusive discount agreements pursuant to 130a subsection 8 sgb v to products containing the substance hydromorphone
(atc code n02aa03 - in the dosage form hard capsule in the dosage strengths 1.
The approval of an extended-release formulation of the potent opioid agonist hydromorphone
was accompanied by a risk management plan aimed at reducing abuse and minimizing diversion of the drug, a notorious problem with the controlled-release opioid agonist oxycodone.
Special Considerations: Only for opioid-tolerant patients on opioid therapy, who require a minimum total daily opiate dose equal to 12 mg of oral hydromorphone
sales for Hydromorphone
Hydrochloride Injection 10mg/ml in 1ml, 5ml, and 50ml doses were approximately $28 million in 2009.